Adverum Biotechnologies, Inc. (NASDAQ:ADVM - Get Free Report) major shareholder Braden Michael Leonard bought 30,600 shares of the firm's stock in a transaction dated Thursday, March 20th. The stock was purchased at an average cost of $5.61 per share, with a total value of $171,666.00. Following the transaction, the insider now directly owns 2,722,761 shares in the company, valued at approximately $15,274,689.21. This represents a 1.14 % increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Major shareholders that own more than 10% of a company's shares are required to disclose their sales and purchases with the SEC.
Braden Michael Leonard also recently made the following trade(s):
- On Tuesday, March 18th, Braden Michael Leonard purchased 62,341 shares of Adverum Biotechnologies stock. The stock was purchased at an average cost of $4.69 per share, for a total transaction of $292,379.29.
Adverum Biotechnologies Price Performance
ADVM stock opened at $5.60 on Friday. The company has a market cap of $116.49 million, a P/E ratio of -0.93 and a beta of 1.14. The stock's fifty day moving average price is $4.42 and its 200-day moving average price is $5.85. Adverum Biotechnologies, Inc. has a 1 year low of $3.52 and a 1 year high of $17.65.
Wall Street Analysts Forecast Growth
Separately, StockNews.com lowered shares of Adverum Biotechnologies from a "hold" rating to a "sell" rating in a research note on Thursday, December 19th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $27.83.
Check Out Our Latest Report on ADVM
Hedge Funds Weigh In On Adverum Biotechnologies
A number of hedge funds have recently made changes to their positions in ADVM. BNP Paribas Financial Markets increased its holdings in shares of Adverum Biotechnologies by 177.0% in the third quarter. BNP Paribas Financial Markets now owns 4,146 shares of the biotechnology company's stock worth $29,000 after purchasing an additional 2,649 shares during the last quarter. Captrust Financial Advisors purchased a new stake in shares of Adverum Biotechnologies during the third quarter valued at $71,000. Wells Fargo & Company MN boosted its holdings in shares of Adverum Biotechnologies by 27.8% in the fourth quarter. Wells Fargo & Company MN now owns 12,240 shares of the biotechnology company's stock valued at $57,000 after purchasing an additional 2,659 shares during the period. MetLife Investment Management LLC increased its stake in shares of Adverum Biotechnologies by 129.1% during the third quarter. MetLife Investment Management LLC now owns 12,582 shares of the biotechnology company's stock valued at $88,000 after buying an additional 7,089 shares during the period. Finally, Zacks Investment Management bought a new stake in shares of Adverum Biotechnologies in the 3rd quarter valued at about $89,000. Institutional investors own 48.17% of the company's stock.
About Adverum Biotechnologies
(
Get Free Report)
Adverum Biotechnologies, Inc, a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
